Pursuant to the share transfer agreement entered into by Swedish Orphan Biovitrum in August 2005 in connection with the acquisition of Arexis AB (“Arexis”), the vendors of Arexis are entitled to milestone payments, in cash and by issuance of shares, upon achievement of certain milestones related to Swedish Orphan Biovitrum’s Kiobrina project. Positive results from such studies were announced in a press release on April 21, 2010.

Please read the whole press release here.